Giuseppe Gargiulo et al. JACC 2018;71:

Slides:

Advertisements

Similar presentations

Gregg W. Stone MD for the ACUITY Investigators Gregg W. Stone MD for the ACUITY Investigators A Prospective, Randomized Trial of Bivalirudin in Acute Coronary.

Advertisements

Giuseppe Biondi-Zoccai Division of Cardiology, University of Turin, Turin, Italy.

Effect of Switching Antithrombin Agents for Primary Angioplasty in Acute Myocardial Infarction The HORIZONS-SWITCH Analysis HORIZONS AMI Dangas G, et al.

比伐卢定在 STEMI 中的应用价值王乐丰首都医科大学附属北京朝阳医院心脏中心. Goals of STEMI PCI Establish reperfusion of IRA ASAP Limit complications Limit costs Achieve excellent long.

Glycoprotein IIb/IIIa inhibitors and bivalirudin: under utilised? Azfar Zaman Freeman Hospital Newcastle-upon-Tyne.

Risk profile and benefits from Gp IIb-IIIa inhibitors among patients with ST-segment elevation myocardial infarction treated with primary angioplasty:

Gregg W. Stone MD for the ACUITY Investigators Gregg W. Stone MD for the ACUITY Investigators A Prospective, Randomized Trial of Bivalirudin in Acute Coronary.

Gregg W. Stone MD for the ACUITY Investigators A Prospective, Randomized Trial of Bivalirudin in Acute Coronary Syndromes Final One-Year Results from the.

Date of download: 6/26/2016 Copyright © The American College of Cardiology. All rights reserved. From: Drug-Eluting Versus Bare-Metal Stents During PCI.

Date of download: 7/8/2016 Copyright © The American College of Cardiology. All rights reserved. From: Comprehensive Meta-Analysis of Safety and Efficacy.

Date of download: 7/9/2016 Copyright © The American College of Cardiology. All rights reserved. From: Relationship between heparin anticoagulation and.

Date of download: 7/9/2016 Copyright © The American College of Cardiology. All rights reserved. From: ACC/AHA guidelines for percutaneous coronary intervention.

Date of download: 7/11/2016 Copyright © The American College of Cardiology. All rights reserved. From: Small molecule glycoprotein IIb/IIIa receptor inhibitors.

From: Bivalirudin Versus Heparin With or Without Glycoprotein IIb/IIIa Inhibitors in Patients With STEMI Undergoing Primary Percutaneous Coronary Intervention:

Date of download: 11/12/2016 Copyright © The American College of Cardiology. All rights reserved. From: Efficacy and Safety of Dual Antiplatelet Therapy.

Heparin Should be the First-line Therapy for Patients with ACS/AMI

Figure 1 Ischaemic endpoints

Supplementary Table 1 Independent Predictors of 2-Year Mortality

For the HORIZONS-AMI Investigators

Initial pharmacotherapy for ST-segment elevation myocardial infarction

Initial pharmacotherapy for ST-segment elevation myocardial infarction

Ischaemic Heart Disease Acute Coronary Syndrome

Impact of gender on the safety and effectiveness of bivalirudin in patients with acute myocardial infarction undergoing primary angioplasty L Grinfeld,

Dr. Harvey White on behalf of the ACUITY investigators

by Nadine Martel, James Lee, and Philip S. Wells

Duration of Dual Antiplatelet Therapy in Patients with an Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention Chirag Bavishi, MD, MPH,

Robert W. Yeh et al. JACC 2017;70:

Robert W. Yeh et al. JACC 2017;70:

ClinicalTrials.gov Identifier NCT

Drug Rate ratio 95% CI Thiazide diuretics 1.0 Reference ACE inhibitors

Waddah Maskoun et al. JACEP 2016;2:

Figure 2 Ischaemic and bleeding outcomes in the major clinical trials

Dean J. Kereiakes et al. JACC 2017;70:

Ashish Shukla et al. JACEP 2015;1:41-51

For the HORIZONS-AMI Investigators

For the HORIZONS-AMI Investigators

Efficacy and Safety of Glycoprotein IIb/IIIa Inhibitors During Elective Coronary Revascularization A meta-analysis of randomized trials performed in the.

NIPPON Trial design: Patients undergoing percutaneous coronary intervention were randomized to short-term dual antiplatelet therapy (DAPT) (6 months; n.

% Heparin + GPI IIb/IIIa Bivalirudin +

on behalf of the ACUITY investigators

David J.A. Jenkins et al. JACC 2018;71:

John A. Bittl et al. JACC 2016;68:

Mintu P. Turakhia et al. JACEP 2016;2:

Nat. Rev. Cardiol. doi: /nrcardio

Efficacy and Safety of Glycoprotein IIb/IIIa Inhibitors During Elective Coronary Revascularization A meta-analysis of randomized trials performed in the.

Matthew Oster et al. JACC 2019;73:

Prabhat Kumar et al. JACEP 2016;j.jacep

Impact of advanced age on the safety and effectiveness of bivalirudin in patients with acute myocardial infarction undergoing primary angioplasty: The.

Do the EXCEL and NOBLE Trial Results Change Meta-Analysis Findings?

Flow diagram for exclusions of trials identified RCT indicates randomized controlled trial Hulten E, et al. Arch Intern Med 2006;166:

OASIS-5: Study Design Randomize N=20,078 Enoxaparin (N=10,021)

BRIGHT Trial design: Patients undergoing PCI for ACS were randomized in a 1:1:1 fashion to receive either bivalirudin alone, unfractionated heparin (UFH)

Seung-Yul Lee et al. JCIN 2018;j.jcin

Forest plot of adjusted odds ratios (with 95% confidence intervals) from multivariable multinomial logistic regression analysis (table 4), by number of.

Davide Capodanno et al. JCIN 2009;2:

Any, acute and subacute stent thrombosis with bivalirudin versus unfractionated heparin (UFH) in predominantly ST segment elevation myocardial infarction.

Associations between type of MI and incident HF

Major bleeding with bivalirudin versus unfractionated heparin (UFH) in predominantly ST segment elevation myocardial infarction (STEMI) studies; (A) glycoprotein.

Zachary L. Steinberg et al. JACC 2017;69:

Pamela E. Scott et al. JACC 2018;71:

MRRs and EMRRs for women with ACS

Christian Madelaire et al. JCHF 2018;6:

Ticagrelor versus prasugrel; risk ratio with 95% CIs for the primary composite end point, primary composite end point in those undergoing PCI, myocardial.

Pamela E. Scott et al. JACC 2018;71:

Major bleeding with bivalirudin versus unfractionated heparin (UFH) in predominantly non-ST segment elevation acute coronary syndrome (NSTE-ACS) studies;

Michael Reed et al. JCIN 2009;2:

Forest plot of adjusted incidence rate ratio for the primary outcome of rt-PA use for catheter malfunction, and secondary outcomes of bacteremia and catheter.

Omar Abdul-Jawad Altisent et al. JCIN 2016;9:

Gianluigi Savarese et al. JCHF 2016;4:

Adjusted. ORs for outcomes by maintenance P2Y12 treatment

Presentation transcript:

Giuseppe Gargiulo et al. JACC 2018;71:1231-1242 Bivalirudin or Heparin in ACS: Forest Plots of Main Outcomes Multivariable adjusted rate ratios (RR) of main outcomes at 30 days for (A) bivalirudin versus unfractionated heparin (UFH) alone or (B) bivalirudin versus UFH plus planned glycoprotein IIb/IIIa inhibitors (GPIs) comparisons. BARC = Bleeding Academic Research Consortium; CI = confidence interval; MI = myocardial infarction; ST = stent thrombosis. Giuseppe Gargiulo et al. JACC 2018;71:1231-1242 2018 American College of Cardiology Foundation